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Sir,
Stattin and Kaaks’s data show that insulin levels increase with
tumour stage, which is what we reported. They do not have a large
enough sample size (sufficient statistical power) to conclude that
there is no difference in the insulin levels of the groups in the table.
I suggest that Stattin and Kaaks collect a larger sample after
determining the sample size; they need to provide 90% power of
detecting a significant (P¼0.05 two-tailed) result. Also, they might
want to measure fasting insulin before breakfast to reduce the
variability of the data, since insulin levels fluctuate throughout the
day and after meals. In the meantime, I refer Stattin, Kaaks and all
interested readers to the article by Altman and Bland (1995), which
eloquently explains the pitfalls of concluding clinical insignificance
when differences between sets of small sample size are found to be
statistically nonsignificant.
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